garadacimab

all catalysts(0)

nothing on the calendar yet

News(2)

• Chiesi to buy KalVista in $1.9B deal for rare disease drug
  The acquisition is the fifth of a biotech company so far this week and, according to some Wall Street analysts, proves pharma’s interest in new and emerging oral therapies for hereditary angioedema.
  biopharma_dive · 3mo ago
• Intellia CRISPR drug succeeds in late-stage study against rare swelling disorder
  The findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.
  biopharma_dive · 3mo ago